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http:WHAT THIS PAPER ADDS
We hypothesised that patients with critical and acute limb ischaemia would have increased levels of plas-
minogen activator inhibitor-1 (PAI-1), leading to a prothrombotic state. The investigation showed a great in-
dividual variability in PAI-1 levels, with a large proportion of the patients having increased levels prior to
treatment. An effective treatment of the ischaemic state normalised those levels, and it seemed that open
surgery was more effective than endovascular treatment in this respect. Further studies on the prothrombotic
state during and after treatment may result in better adjuvant treatment.Objective/background: Patients with peripheral arterial occlusive disease (PAOD), in particular critical limb
ischaemia (CLI), carry a high risk of thrombotic events. We hypothesised that patients undergoing conservative,
endovascular, or open surgical treatment for CLI have increased levels of plasminogen activator inhibitor-1
(PAI-1), leading to a prothrombotic state. The objective was to determine levels of PAI-1 in patients with acute or
chronic PAOD/CLI.
Methods: Thirty-two patients with a median age of 74 (49e90) years were included. Three underwent
thrombolysis for acute limb-threatening ischaemia. Twenty-six patients with chronic ischaemia received
endovascular (n ¼ 20) or open (n ¼ 6) surgical treatment. Three were treated conservatively. Biomarkers and
ankle brachial index (ABI) were measured before and up to 1 month after intervention. Patency was studied with
repeated duplex ultrasound.
Results: Ankle pressure and ABI improved after intervention (p < .001). C-reactive protein (CRP) increased from a
median of 7.90 mg/L at baseline to 31.5 on day 1 (p < .001), 28.0 on day 6 (p < .001), and returned to baseline
levels on day 30. PAI-1 antigen and activity decreased from day 6 and onwards post-intervention compared with
baseline (p < .05). A great individual variability in PAI-1 antigen and activity was observed. Although most
actively treated patients had normal PAI-1 activity, 11/29 (38%) were above that level of normality at baseline,
10/24 (42%) on day 1, 3/23 (13%) on day 6, and 5/27 (19%) on day 30 after intervention.
Conclusion: Endovascular and open surgical treatment resulted in improved ankle pressure and ABI. The
intervention was followed by a transient increase in CRP and a sustained reduction in PAI-1 levels and activity.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Patients with peripheral arterial occlusive disease (PAOD)
and, in particular, those with the most severe form of
disease, critical limb ischaemia (CLI), carry a high risk of
thrombotic events.1 The prothrombotic state results in anresponding author. M. Björck, Department of Surgical Sciences,
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//dx.doi.org/10.1016/j.ejvs.2013.05.011increased risk of general cardiovascular events and local
arterial thrombosis after intervention.1 Antiplatelet therapy
with 75e325 mg acetylsalicylic acid (ASA)/day reduced the
number of vascular events by 25% and the number of re-
occlusions after coronary artery bypass graft (CABG),
percutaneous transluminal coronary angioplasty, percuta-
neous transluminal angioplasty (PTA), or femoro-popliteal
bypass by 40%.2 The Clopidogrel versus Aspirin in Patients
at Risk of Ischaemic Events (CAPRIE) study showed a further
risk reduction by using clopidogrel instead of ASA.3
Although the relative risk reduction was similar in
different subgroups, the absolute risk reduction was greater
among patients with multiple risk factors, which is typical
M. Björck et al. 215for PAOD patients.4 The importance of coagulation was
shown in the Dutch Bypass Oral Anticoagulants or Aspirin
study,5 which randomised 2,621 patients after femoro-
popliteo-distal bypass to receive ASA or anticoagulation.
Patients with anticoagulation had better patency when a
vein graft was used, but ASA was more effective with a
prosthetic graft. That postoperative antiplatelet therapy is
better with a prosthetic graft was recently veriﬁed in the
Clopidogrel and Acetylsalicylic Acid in bypass Surgery for
Peripheral Arterial Disease trial.6 In other therapeutic situ-
ations, such as after endovascular treatment or venous
bypass, coagulation and ﬁbrinolysis can be equally impor-
tant targets for secondary prophylaxis.
Critical for ﬁbrinolysis is the activation of plasminogen to
plasmin, the active enzyme responsible for the degradation
of ﬁbrin. Fibrin provides the basic framework for the for-
mation of a blood clot. The role of plasminogen activator
inhibitor-1 (PAI-1) is to stabilise a formed clot by inhibiting
the plasminogen activator (t-PA). In a diseased state this
activity can become prothrombotic.
Recent data from patients with thrombosis, such as those
with acute myocardial infarction,7 as well as patients with
risk factors for thrombosis, such as obesity,8 show elevated
PAI-1 levels. Progression of PAI-1 levels over time, as well as
high baseline levels, is also associated with incident type 2
diabetes9dpossibly the most important risk factor for
PAOD/CLI. A direct pathogenetic connection between these
elevated PAI-1 levels and the risk of thrombosis has, how-
ever, not yet been established in humans. Theoretically,
inhibition of PAI-1 could be beneﬁcial for a patient at
elevated risk of thrombosis/vascular occlusion. Additionally,
animal experiments with models of thrombosis have shown
that thrombus formation can be prevented by inhibiting
PAI-1 with antibodies10 or with PAI-1 antagonists.11
The primary aim of this study was to characterise the
absolute levels and changes in circulating concentration of
PAI-1 and PAI-1 activity among patients with acute or
chronic PAOD/CLI before and after conservative, endovas-
cular, or open surgical treatment. As there were no previous
data on this group of patients no power calculation was
possible and the study was hypothesis-generating. A sec-
ondary aim was to study the logistics of including patients
with CLI into clinical trials on PAOD.Baseline Intervention Post-intervention
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Figure 1. Study design: clinical assessments and bloPATIENTS AND METHODS
Study design
This was a prospective study in patients with limb-
threatening lower limb ischaemia referred to the Depart-
ment of Vascular Surgery in Uppsala for possible revascu-
larisation. The study protocol was approved by the Regional
Ethics Committee of the Uppsala/Örebro region. All patients
gave oral and written informed consent. The study design is
described in Fig. 1.Inclusion/exclusion criteria
The aim was to include all eligible patients with limb-
threatening acute or chronic lower limb ischaemia,
who had infrainguinal disease. Predeﬁned exclusion criteria
were age below 18 years; need for immediate amputation;
intolerance to blood sampling owing to anaemia (haemo-
globin < 100 g/L) or lack of peripheral veins suitable for
blood-sampling; previous intervention for lower limb
ischaemia within the last 3 months; mental condition not
allowing informed consent; or practical problems prevent-
ing follow-up and/or blood-sampling.
Enrolled patients in whom blood samples could not be
obtained at baseline or after intervention were excluded
from analysis.Subgroups based on planned interventions
Based on the planned interventions, four predetermined
subgroups were deﬁned (Table 1). Although open surgical
embolectomy, thrombectomy, and bypass surgery are still
performed, the standard contemporary treatment for acute
lower limb ischaemia is catheter-guided thrombolysis, fol-
lowed by subsequent PTA and/or stenting. This subgroup of
patients has a high risk of cardiovascular thrombotic
events,1 and was thought to be of particular interest to
study.
Chronic CLI was deﬁned as Fontaine’s stages IIIeIV or
Rutherford’s categories 4e6.1 Rest pain (Rutherford 4) had
a minimum duration of 4 weeks and required morphine-like
analgesia. In patients with chronic CLI, where revascular-
isation was not possible, the intervention used was pain
relief and, if necessary, amputation at a later date. TheMedical records and telephone 
contact with the patients :
- Clinical vascular events 
and vessel status
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Figure 2. Screened, included, and excluded patients.
Table 1. Predetermined subgroups in the 32 patients studied.
Subgroup No. of patients %
Thrombolysis for acute lower limb
ischaemia
3 8.8
Pain relief/amputation for CLI 3 8.8
Endovascular treatment for CLI 20 64.7
Open surgical treatment for CLI 6 17.6
Note. CLI ¼ chronic critical limb ischaemia.
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contemporary context as in most centres approximately
90% undergo active revascularisation.1 Based on historical
data it is estimated that 1 year after diagnosis 25% of pa-
tients have died, 30% are amputated, and 45% are still alive
with two intact limbs.12,13
Most patients in the current study underwent revascu-
larization. Endovascular treatment (PTA/stent/subintimal
angioplasty, or a combination of these modalities) was the
ﬁrst-choice treatment. Open surgical treatment was per-
formed when endovascular treatment was difﬁcult, or even
impossible, and if the patient was considered to tolerate an
open procedure. Open procedures included femoro-
popliteal or femoro-crural bypass (with either autologous
vein or expanded polytetraﬂuoroethylene graft), sometimes
combined with trombendarterectomy in the common
femoral artery, or PTA to improve inﬂow or outﬂow of the
bypass.
Six patients in the endovascular group and two in the
group treated conservatively had an additional endovas-
cular intervention during the 6-month study period, but not
within 1 month of recruitment. Thus, in total, 40 in-
terventions were carried out in 32 patients, but laboratory
samples speciﬁc for this investigation were only taken in
conjunction with the ﬁrst intervention.
Biomarker assessments
Blood was collected before and after intervention, and
stored frozen (70 C) until analysis. All blood samples
were taken between 8.00 a.m. and 10.00 a.m., to avoid
confounding due to the circadian variation in PAI-1 levels.
Standard clinical blood chemistry was measured at the
Clinical Chemistry Laboratory at Uppsala University Hospital,
Uppsala, Sweden. PAI-1 antigen and activity, D-dimer, and C-
reactive protein (CRP) in plasma were all determined at the
Clinical Chemistry Laboratory at Sahlgrenska University
Hospital, Gothenburg, Sweden, using standard methods.
For this investigation the deﬁnition of the upper limit of
normality for PAI-1 activity is crucial, and was measured
with a Chromolize immunoassay test (Trinity Biotech, Bray,
Ireland). The Clinical Chemistry Laboratory at Sahlgrenska
University Hospital uses an upper limit of 21 IU/mL, based
on approximately 40 healthy individuals, whose blood
samples were obtained in 1996e97. In a recent publication,
1,016 patients aged 70 years were investigated in the Pro-
spective Investigation of the Vasculature in Uppsala Seniors
(PIVUS) study,13 in which obesity and metabolic syndrome
were associated with elevated PAI-1 levels. In the PIVUSstudy, 319 patients were identiﬁed to have a normal body
mass index (BMI) (<25), and no signs of metabolic syn-
drome. This subgroup had a mean level of PAI-1 activity of
5.1 IU/mL (SD: 6.6), measured using the same laboratory
method. Based on this larger experience of veriﬁed healthy
individuals in a similar age group from the same geographic
area, we decided to deﬁne the upper limit of normality as
5.1 þ 2  6.6 ¼ 17.7 IU/mL, approximated to 18 IU/mL.
Another important factor for the interpretation of the
results is the coefﬁcient of variation (CV) of the assays used.
For the a Chromolize immunoassay test used to calculate
PAI-1 activity the CV in the interval 2e36 IU/mL was 3.7% at
the 2 IU/mL level, 2.7% at the 22 IU/mL level, and 2.6% at
the 36 IU/mL level. The TriniLize PAI-1 antigen immunoassay
(Trinity Biotech, Jamestown, NY, USA) has a CV of 1.9% at
20 ng/mL and 2.9% at 40 ng/mL.
The blood sampling was scheduled for a total of 8e9
occasions (Fig. 1). Blood sampling on days 2 and 3 was only
performed if the patient was still in hospital, which was
not always the case after conservative or endovascular
treatment.
Clinical assessments and duplex ultrasound
Vessel status assessment was performed pre-intervention,
at 1 week and 1 month post-intervention based on clin-
ical examination, ankle and brachial blood pressure mea-
surements, and duplex ultrasound. Calculation of ankle
brachial index (ABI) was performed. Toe-pressure mea-
surements were not performed. Assessments at 3 and 6
months were made via telephone calls and review of the
patients’ medical records (Fig. 1).
Study patient recruitment
Seventy-four patients were screened for participation with
an aim to include 40 and to be able to evaluate at least 32.
Thirty-ﬁve consecutive patients were found eligible and
were enrolled in the study between September 2009 and
April 2010 (Fig. 2). Uppsala is a regional tertiary care centre,
serving a sparsely populated region. Some patients could
not be included owing to transport problems. Dementia and
other mental conditions precluding informed consent were
other common exclusion criteria.
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within 3 months, and were not recruited as the prior
intervention could have affected coagulation/ﬁbrinolysis.
Four patients were not included because of pre-
intervention haemoglobin <100 g/L, and one patient
lacked veins suitable for blood-sampling. Four patients
could, from a medical point of view, have been recruited,
but emergency situations resulted in failure of pre-
intervention blood sampling.
Two enrolled patients, both in the endovascular group,
were excluded because of problems with blood-sampling. In
the ﬁrst patient, who was enrolled in an emergency situa-
tion, the baseline blood sample was lost. The other patient,
who was on renal replacement therapy, lacked suitable
veins so that post-intervention blood sampling had to be
discontinued from an ethical stand-point. One patient
withdrew consent to participate in the study.Statistical methods
The study sample size was not based on any formal
sample size calculation owing to the explorative character
of the study. The longitudinal changes in the primary
variables, PAI-1 antigen and PAI-1 activity, were explored
graphically and by descriptive statistics. The degree of
intra-individual change between baseline (pre-interven-
tion) and post-intervention levels of biomarkers at
different time points were assessed by p-values of statis-
tical tests. In the group of all patients and those with
invasive intervention the logarithms of the biomarkers
were approximately normal, and a paired t-test was used.
For the groups and variables where the normality was
questioned, for example in the small open surgery group,
Wilcoxon signed-rank test was used for statistical com-
parisons. No correction for multiple comparisons was
performed.Table 2. Baseline characteristics in the 32 patients evaluated.
Variable Unit V
Age years 7
Sex M/F
Acute limb ischaemia e e
Rest pain Rutherford 4
Ischaemic ulcer Rutherford 5
Gangrene Rutherford 6
Ankle pressure on inclusion mmHg 8
Never smoked
Previous smoker
Current smoker
Body weight kg 7
Height cm 1
BMI kg/m2 2
Diabetes
History of cardiac disease
Creatinine mmol/L 1
Haemoglobin g/L 1
Leucocytes 109/L 9
Platelets 109/L 3
Note. BMI ¼ body mass index; M ¼ male; F ¼ female.RESULTS
Study population and baseline characteristics
Thirty-two patients were included who were conservatively
(n ¼ 3), endovascularly (n ¼ 23), or surgically treated
(n ¼ 6). Baseline characteristics are summarised in Table 2.
Median age was 74 years (range 49e90 years), the endo-
vascular group was older (median 77 years) than the other
groups (median 70e71 years). The patients with chronic CLI
were rather equally distributed between the Rutherford 4,
5, and 6 categories. The high mean ankle pressure of
81 mmHg is explained by a large number of patients with
incompressible arteries due to diabetes. In six patients the
ankle pressure was zero.
Eight patients (25%) were active and 16 (50%) were
former smokers. BMI was >25 in 20 patients (59%), and
>30 in seven (21%). Eighteen had diabetes (56%) treated
with insulin, often in combination with oral medication.
Twenty patients (59%) had a medical history of cardiac
disease, 14 (41%) had coronary artery disease, and 6 (18%)
had atrial ﬁbrillation or valvular disease. Three had under-
gone CABG; two had percutaneous coronary intervention.
Mean creatinine level was 136 mmol/L; three were on renal
replacement therapy. Previous vascular surgical history
included 11 endovascular and six open procedures for lower
limb ischaemia, two major amputations, two operations for
abdominal aortic aneurysms, and one carotid artery end-
arterectomy. At entry, 25 patients (74%) were treated with
low dose ASA, three with dikumarol (8.8%), and 10 were on
low-molecular weight heparin (29%).Surgical outcome and major complications
The median ankle pressure increased from 75 mmHg (range
0e250 mmHg) at baseline to 140 mmHg (range 60e
220 mmHg, p < .01 compared with baseline) 6 days afteralue (mean/SD) Frequencies %
3 (11) 32
20/12 63.0/38.0
3 9.4
13 41.0
9 28.0
7 22.0
1 (60) 32
10 31.0
14 44.0
8 25.0
8 (13) 31
72 (8) 31
6 (3) 31
18 56.0
19 59.0
36 (111) 32
28 (16) 32
(3) 32
02 (111) 32
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compared with baseline) 30 days after intervention among
the 23 patients who underwent endovascular treatment.
The median ABI increased from 0.46 (range 0e1.57) at
baseline to 1.02 (range 0.38e1.69, p < .01 compared with
baseline) 6 days after endovascular intervention and 1.00
(range 0e1.83, p < .01 compared with baseline) 30 days
after endovascular intervention (Fig. 3).
One patient suffered a myocardial infarction, another a
stroke. There was no 30-day mortality, but during the 6-
month follow-up one patient died from combined renal
and heart failure. There was no major amputation, but two
toe amputations. One patient was re-operated on for a
postoperative bleeding.
Biomarkers
The three patients who were treated conservatively had
similar levels of the targeted biomarkers at baseline as the
29 who underwent active therapy, and their biomarkers
were virtually unchanged during the 30-day follow-up
period. They are not further included in the analysis,
which is focused on the two main intervention groups:
endovascular treatment (n ¼ 23) and open surgical treat-
ment (n ¼ 6).Figure 3. Ankle-brachial index (ABI) at baseline and 6 and 30 days a
treatment (including thrombolysis); (B) patients who had open surge
baseline (paired t-test for A and C; signed-rank test for B). The boxes rep
1.58 IQR/sqrt(n). Outliers are excluded from the ﬁgure statistics.The median (range) high sensitive CRP measured in
serum in the 23 patients who underwent endovascular
treatment increased from 5.80 mg/L (0.68e85.0 mg/L) at
baseline, to 25.0 mg/L (1.10e110 mg/L, p < .001) the ﬁrst
day after intervention and 24.0 mg/L (3.30e130 mg/L,
p < .01) 6 days after intervention. One month post-
endovascular intervention the CRP values had returned to
baseline levels 10.0 mg/L (1.20e94.0 mg/L), p ¼ .746)
(Fig. 4).
Neither PAI-1 antigen nor PAI-1 activity increased post-
intervention compared with baseline at the measured
time points at a group level, as shown in Table 3. In
contrast, from day 6 onwards there was a signiﬁcant
reduction in PAI-1 levels and activity (Figs. 5 and 6).
The variability of PAI-1 antigen and PAI-1 activity are
described at the main assessment time points, in the two
treatment groups, as well as for all treated patients, as box-
plots in Figs. 5 and 6. The upper limit of normality for PAI-1
activity is given as a reference line in Fig. 6.
Although most patients were within the limit of
normality for PAI-1 activity, it can be noted that among the
actively treated patients, 11/29 (38%) were above that limit
at baseline, 10/24 (42%) on day 1, 3/23 (13%) on day 6, and
5/27 (19%) 30 days after intervention.fter intervention or surgery. (A) Patients who had endovascular
ry; (C) all patients. Signiﬁcance (p-values) indicates change from
resent median and interquartile range (IQR). The notches extend to
Figure 4. Sensitive C-reactive protein (S-CRP) at baseline, and 1, 6, and 30 days after intervention or surgery. (A) Patients who had
endovascular treatment (including thrombolysis); (B) patients who had open surgery; (C) all patients. Signiﬁcance (p-values) indicates
change from baseline (paired t-test for A and C; signed-rank test for B). The boxes represent the median and interquartile range (IQR). The
notches extend to 1.58 IQR/sqrt(n). Outliers are excluded from the ﬁgure statistics, but not from the signiﬁcance testing.
M. Björck et al. 219DISCUSSION
In this exploratory study on patients with CLI, the longi-
tudinal changes in the primary variables, PAI-1 antigen
and PAI-1 activity, did not show the expected increase
post-intervention at a group level. There was, however,
a signiﬁcant reduction in PAI-1 levels and activity
compared with pre-treatment levels, indicating that the
ischaemic state was an important factor explaining high
levels prior to therapy. This is in line with a previous
investigation that reported an up-regulation of PAI-I by
hypoxia.14
Furthermore, great variability in the PAI-1 levels was
observed, and a substantial fraction of the patients had
levels of PAI-1 activity above the deﬁned threshold value.
That was an expected ﬁnding, given the fact that conditions
associated with increased levels of PAI-1,8 such as over-
weight/obesity and diabetes/metabolic syndrome, are
common in this group of patients.15
If individual patients with elevated levels of PAI-1 are
associated with an increased risk of thrombotic complica-
tions, and if therapeutic measures aimed at lowering PAI-1
levels may affect outcome in this group of patients, remains
to be shown. The study was not designed to determine
whether elevated levels of PAI-1 activity were associated
with an increased risk of adverse events.The pro-thrombotic state of patients who have under-
gone revascularisation for CLI is multifactorial. All of the
following factors are consequences of ischaemia/reperfu-
sion, as well as surgical trauma: immobilisation, inﬂamma-
tion, activation of thrombocytes, elevated levels of
ﬁbrinogen, and the studied inhibition of ﬁbrinolysis. It is
interesting to note (in Figs. 4 and 6) that the response to
open surgery seems to be somewhat different to that of
endovascular intervention. The early inﬂammatory response
was greater after open surgery, but after 30 days all the
patients operated on had normalised CRP, whereas a large
proportion of the endovascularly-treated patients still had
elevated levels 30 days post-intervention (Fig. 4). The effect
on PAI-1 activity, however, did not vary depending on the
type of treatment (Fig. 6). One possibility is that open
surgery results in a more effective reversal of the ischaemic
state. The size of the current study, however, limited the
possibility of performing subgroup analyses.
One limitation is that, for ethical reasons, we had to limit
the blood sampling. We aimed to study the entire post-
operative period (30 days). As a consequence, the possi-
bility of a short-term elevation of PAI-1 occurring during the
ﬁrst few hours after surgery or intervention cannot be
excluded. This is a period, however, when thromboprophy-
laxis is maintained with multiple drugs. The patients were
Table 3. Differences in biomarker levels between baseline and post-intervention.a
Biomarker Day Median (range) Patients (n) pb
D-dimer (ELISA) (mg/L) Baseline (day 0) 1.00 (0.33e7.50) 29 e
Change day 1-0 0.15 (4.80 to 1.94) 24 0.100
Change day 6-0 0.60 (5.40 to 2.20) 23 0.002
Change day 14-0 0.74 (4.80 to 4.10) 20 0.000
Change day 21-0 0.46 (5.50 to 2.60) 22 0.004
Change day 30-0 0.16 (5.60 to 2.41) 27 0.017
P-PAI-1-activity (kIE/L) Baseline (day 0) 14.0 (0.60e69.00) 29 e
Change day 1-0 0.35 (31.00 to 122.00) 24 0.791
Change day 6-0 5.0 (58.00 to 12.60) 23 0.019
Change day 14-0 3.6 (55.00 to 29.00) 20 0.018
Change day 21-0 4.7 (49.00 to 46.00) 22 0.033
Change day 30-0 8.0 (36.00 to 43.00) 27 0.000
P-PAI-1-antigen (mg/L) Baseline (day 0) 19.5.3 (7.40e53.80) 29 e
Change day 1-0 2.00 (17.00 to 84.80) 24 0.047
Change day 6-0 60 (36.00 to 9.80) 23 0.102
Change day 14-0 2.8 (22.00 to 19.80) 20 0.026
Change day 21-0 6.2 (32.00 to 30.40) 22 0.071
Change day 30-0 4.9 (32.00 to 21.70) 27 0.000
Note. ELISA ¼ enzyme-linked immunosorbent assay; PAI-1 ¼ plasminogen activator inhibitor-1.
a Only 29 patients who underwent surgery/endovascular intervention are included in this analysis.
b p refers to comparisons between baseline and the day indicated.
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heparin during surgery/intervention and low molecular
weight heparin during the postoperative period as pro-
phylaxis for venous thrombo-embolism. Thus, an early peakFigure 5. Plasminogen activator inhibitor-1 (PAI-1) antigen at baseline, an
who had endovascular treatment (including thrombolysis); (B) patients
dicates change from baseline (paired t-test for A and C; signed-rank te
(IQR). The notches extend to 1.58 IQR/sqrt(n). Outliers are excludedin PAI-1 is unlikely to constitute a clinical problem, and this
was the rationale for focusing the blood sampling on the
later postoperative period. All the drugs affecting throm-
bosis and haemostasis are potential confounders, but it wasd 1, 6, 14, 21, and 30 days after intervention or surgery. (A) Patients
who had open surgery; (C) all patients. Signiﬁcance (p-values) in-
st for B). The boxes represent the median and interquartile range
from the ﬁgure statistics, but not from the signiﬁcance testing.
Figure 6. Plasminogen activator inhibitor-1 (PAI-1) activity at baseline, and 1, 6, 14, 21, and 30 days after intervention or surgery. (A)
Patients who had endovascular treatment (including thrombolysis); (B) patients who had open surgery; (C) all patients. Signiﬁcance (p-
values) indicates change from baseline (paired t-test for A and C; signed-rank test for B). The boxes represent the median and interquartile
range (IQR). The notches extend to 1.58 IQR/sqrt(n). Outliers are excluded from the ﬁgure statistics, but not from the signiﬁcance testing.
Horizontal lines represent the upper limit of normality as deﬁned in the ‘Patients and Methods’ section.
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patients. However, the patients were treated in a very
similar way, as this was a single-centre study in an academic
unit with strict management guidelines. Furthermore, most
comparisons were made in a matched design, on the same
patients before and after treatment, thus minimising the
risk of confounding.
Patients with CLI are often elderly with multiple comor-
bidities, including mental disorders.1 The CAPRIE study
showed that patients with PAOD had more generalised
atherosclerosis than other subgroups of patients with car-
diovascular disease,3 and this ﬁnding was veriﬁed in many
other investigations.1,16 Designers of clinical trials often
prefer to study claudicants instead of patients with CLI, with
the rationale that this group is easier to recruit owing to the
higher prevalence and more stable nature of their disease,
and the fact that they are younger. A secondary aim of this
investigation was to study the logistics of including patients
with CLI. Approximately half of the patients screened were
recruited, resulting in 32 patients being studied over 6
months at this hospital, which has a primary catchment
area of 320,000 people. Some of the exclusion criteria, such
as prior intervention or anaemia, may not apply to other
trials. This information may be of interest to researchers
planning trials on patients with PAOD. The inclusion ofpatients with CLI often results in more cardiovascular
events and thus could reduce the sample size, depending
on the studied outcome measures and the mechanism of
action of the investigational drug.
In summary, patients treated with open or endovascular
surgery for acute or chronic CLI demonstrated an inﬂam-
matory response, but no signs of generally inhibited throm-
bolysis deﬁned as an increased activity of PAI-1 during the
postoperative period. In contrast to the hypothesis that the
intervention would increase PAI-1 levels the study showed a
sustained reduction after revascularisation. A fairly large
proportion of the patients did, however, have increased PAI-
1 activity, both at baseline and throughout the postoperative
period. The clinical signiﬁcance of this latter ﬁnding remains
uncertain. Further studies are needed to understand the
thrombogenic environment in patients with PAOD.
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